ABSTRACT
miRNA-489 was shown to be a suppressor factor in many cancers, however, evidence on the effects and mechanism of miRNA-489 in progression of cervical cancer is limited. So we aimed to determine the function of miRNA-489 in cervical cancer proliferation and apoptosis in our present study. Interestingly, we found that miRNA-489 was significantly down-regulated in cervical cancer tissues. miRNA-489 overexpression inhibited the cell proliferation and improved the cell apoptosis of cervical cancer cells. Further, miRNA-489 over-expression suppressed the activation of PI3K and AKT, and stimulated P53 proteins expression. In conclusion, our results suggested that miRNA-489 may be considered as a biomarker in cervical cancer and had suppressed the cell proliferation and stimulated cell apoptosis via PI3K/AKT/P53 signaling pathway (Fig. 5, Ref. 26). Text in PDF www.elis.sk.
Subject(s)
MicroRNAs , Uterine Cervical Neoplasms , Apoptosis , Biomarkers , Cell Line, Tumor , Cell Proliferation , Female , Gene Expression Regulation, Neoplastic , Humans , MicroRNAs/analysis , Phosphatidylinositol 3-Kinases , Proto-Oncogene Proteins c-akt , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/genetics , Uterine Cervical Neoplasms/therapyABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Direct intratumoral injection of nonremovable radioactive material has been widely studied because it could deliver high doses of radiation to target sites and minimize radiation leakage to non-target organs or tissues. Thirty nude mice bearing SMMC 7721 human liver carcinoma were used for the biodistribution study after intratumoral injection of [(188)Re]rhenium sulfide suspension or sodium [(188)Re]perrhenate solution. Another 30 tumor-bearing mice were divided into six groups, four groups of which were treated with a 0.1 ml [(188)Re]rhenium sulfide suspension at doses of 3.7, 7.4, 18.5, 29.6 MBq by a single intratumoral injection. For control studies, to study the tumor inhibiting ratio, the remaining two groups were injected with nonradioactive rhenium sulfide suspension and Hanks' balanced salt solution, respectively. The injections were repeated 6 days later. The retention percentages of radioactivity (%ID) in tumors injected with [(188)Re]rhenium sulfide suspension were 90.96+/-6.63%, 86.09+/-22.58% and 87.62+/-13.97% at 1, 24 and 48 h, respectively. Tumor inhibition ratios are as high as 89% when the outer space of tumor (0.5-0.6 cm from center) received about 507.6 Gy doses. Intratumoral injection of [(188)Re]rhenium sulfide suspension results in high tumor retention indicating this approach has strong potential for the treatment of hepatic carcinoma.
